WebType: Company - Public (HIK) Industry: Biotech & Pharmaceuticals. Revenue: $1 to $5 billion (USD) Competitors: Teva Pharmaceuticals, Sandoz International, Perrigo. Create Comparison. We are a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets we serve through the development, manufacture ... WebApr 30, 2024 · Hikma expects KLOXXADO TM to be available in the second half of 2024. About Naloxone Naloxone hydrochloride is an opioid antagonist that antagonises opioid effects by competing for the same ...
Hikma launches generic Advair Diskus® following FDA approval
WebSep 21, 2024 · Find your career. >4200. employees with 5+ years’ service. c.8700. employees worldwide. Hikma’s US STEM programme for under-represented students. 21 September 2024. #OwnYourCareer Radia Chalabi, Medical Representative, Algeria. 28 November 2024. WebBecause for us, it’s not just business, it’s personal. Get in touch: [email protected] Tel: 1.800.631.2174. For new business or contract manufacturing enquiries please contact: [email protected]. To learn more about our contract manufacturing offer and Columbus facility watch here. cicely sanchez
Voriconazole Hikma (previously Voriconazole Hospira)
WebView All Active Pharmaceutical Ingredients (API) with Drug Master Files (DMF), CEP / COS, Japanese DMFs, Written Confirmation (WC) manufactured or supplied by Hikma Pharmaceuticals on PharmaCompass.com WebDec 31, 2024 · LEI: 549300BNS685UXH4JI75. The Company will today publish on its website, www.hikma.com, the Annual Report for the year ended. 31 December 2024 (the '2024 Annual Report'). Hard copy versions of the following documents will be sent to those shareholders who have elected to receive paper communication on or about 15 April … WebJan 12, 2024 · A district court in Delaware, in Amarin v. Hikma, found that Hikma’s label promoted its drug for severe hypertriglyceridemia, which wasn’t covered by a patent. The court also said public statements that its product is a generic alternative to Vascepa “does not expose Hikma to liability.”. The Amarin decision could provide a “roadmap ... dgr bolton road bury